New drug targets in metastatic melanoma

Journal of Pathology

Volumn 232, Issue 2, 2014, Pages 134-141

  Homet, Blanca ^a   Ribas, Antoni ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BRAF mutant; immunotherapy; metastatic melanoma

Indexed keywords

ANTINEOPLASTIC AGENT; ARRY 438162; B RAF KINASE; B RAF KINASE INHIBITOR; BVD 523; CANCER VACCINE; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; DABRAFENIB; DACARBAZINE; DASATINIB; IMATINIB; IPILIMUMAB; LAMBROLIZUMAB; LGX 818; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MK 3475; NIVOLUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN KINASE B; SCH 772984; SELUMETINIB; SUNITINIB; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

ANTIGEN PRESENTING CELL; ARTHRALGIA; BLURRED VISION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DIARRHEA; DIMERIZATION; DRUG ERUPTION; DRUG FEVER; DRUG TARGETING; EDEMA; FATIGUE; GASTROINTESTINAL TOXICITY; GENE ACTIVATION; GENE MUTATION; HEART EJECTION FRACTION; HUMAN; KERATOACANTHOMA; LIVER FUNCTION TEST; MELANOMA; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROBLASTOMA; ONCOGENE N RAS; OVERALL SURVIVAL; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QT PROLONGATION; RETINOPATHY; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN CARCINOMA; SKIN TOXICITY; TREATMENT DURATION; TREATMENT RESPONSE;

BRAF MUTANT; IMMUNOTHERAPY; METASTATIC MELANOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOTHERAPY; MELANOMA; MOLECULAR TARGETED THERAPY; PHENOTYPE; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84890290450     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4259     Document Type: Review

References (86)

1. American Cancer Society,. Cancer Facts and Figures 2012. American Cancer Society: Atlanta, GA, 2012.
2. Gray-Schopfer V, Wellbrock C, Marais R,. Melanoma biology and new targeted therapy. Nature 2007; 445: 851-857.
3. Lovly CM, Dahlman KB, Fohn LE, et al., Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One 2012; 7: e35309.
4. Long GV, Menzies AM, Nagrial AM, et al., Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29: 1239-1246.
5. Beadling C, Jacobson-Dunlop E, Hodi FS, et al., KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008; 14: 6821-6828.
6. Curtin JA, Fridlyand J, Kageshita T, et al., Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-2147.
7. Wan PT, Garnett MJ, Roe SM, et al., Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855-867.
8. Padua RA, Barrass N, Currie GA,. A novel transforming gene in a human malignant melanoma cell line. Nature 1984; 311: 671-673.
9. Ji Z, Flaherty KT, Tsao H,. Molecular therapeutic approaches to melanoma. Mol Aspects Med 2010; 31: 194-204.
10. Flaherty KT, Puzanov I, Kim KB, et al., Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-819.
11. Sosman JA, Kim KB, Schuchter L, et al., Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-714.
12. Hauschild A, Grob JJ, Demidov LV, et al., Dabrafenib in BRAF-mutated metastatic melanomaa multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365.
13. Gibney GT, Zager JS,. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies. Expert Opin Drug Metab Toxicol 2013; 9: 893-899.
14. Zhang J, Yang PL, Gray NS,. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9: 28-39.
15. Su F, Viros A, Milagre C, et al., RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366: 207-215.
16. Oberholzer PA, Kee D, Dziunycz P, et al., RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012; 30: 316-321.
17. Arkenau HT, Kefford R, Long GV,. Targeting BRAF for patients with melanoma. Br J Cancer 2011; 104: 392-398.
18. Hauschild A, Grob J, Demidov L, et al., An update on BREAK-3a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). J Clin Oncol 2013; 31: abstr. 9013.
19. Shi H, Moriceau G, Kong X, et al., Melanoma whole-exome sequencing identifies (V600E) B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 2012; 3: 724.
20. Poulikakos PI, Persaud Y, Janakiraman M, et al., RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E). Nature 2011; 480: 387-390.
21. Nazarian R, Shi H, Wang Q, et al., Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468: 973-977.
22. Wagle N, Emery C, Berger MF, et al., Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011; 29: 3085-3096.
23. Paraiso KH, Xiang Y, Rebecca VW, et al., PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 2011; 71: 2750-2760.
24. Adjei AA, Cohen RB, Franklin W, et al., Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY142886) in patients with advanced cancers. J Clin Oncol 2008; 26: 2139-2146.
25. Greger JG, Eastman SD, Zhang V, et al., Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 2012; 11: 909-920.
26. Johannessen CM, Boehm JS, Kim SY, et al., COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468: 968-972.
27. Shi H, Kong X, Ribas A, et al., Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res 2011; 71: 5067-5074.
28. Villanueva J, Vultur A, Lee JT, et al., Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010; 18: 683-695.
29. Jiang CC, Lai F, Thorne RF, et al., MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin Cancer Res 2011; 15: 721-730.
30. Atefi M, von Euw E, Attar Net et al. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One 2011; 6: e28973.
31. Deng W, Gopal YN, Scott A, et al., Role and therapeutic potential of PI3K-mTOR signalling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res 2012; 25: 248-258.
32. Smalley KS, Lioni M, Dalla Palma M, et al., Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanoma. Mol Cancer Ther 2008; 7: 2876-2883.
33. Sullivan RJ, Flaherty K,. MAP kinase signaling and inhibition in melanoma. Oncogene 2013; 32: 2373-2379.
34. Flaherty KT, Robert C, Hersey P, et al., METRIC Study Group: improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-114.
35. Infante JR, Fecher LA, Falchook GS, et al., Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametiniba phase 1 dose-escalation trial. Lancet Oncol 2012; 13: 773-781.
36. Colombino M, Capone M, Lissia A, et al., Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. J Clin Oncol 2012; 30: 2522-2529.
37. Gupta A, Love S, Schuh A, et al., DOC-MEK a double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma. J Clin Oncol 2013; 31: abstr. 9068.
38. Ascierto PA, Schadendorf D, Berking C, et al., (2013) MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations a non-randomised, open-label phase 2 study. Lancet Oncol 2013; 14: 249-256.
39. Gajewski T, Salama A, Niedzwiecki D, et al., Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). J Translat Med 2012; 10: 246.
40. Jansen B, Schlagbauer-Wadl H, Kahr H, et al., Novel Ras antagonist blocks human melanoma growth. Proc Natl Acad Sci USA 1999; 96: 14019-14024.
41. Morris EJ, Jha S, Restaino CR, et al., Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov 2013; 3: 742-750.
42. Paraiso KH, Fedorenko IV, Cantini LP, et al., Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 2010; 102: 1724-1730.
43. Kim KB, Lewis KD, Pavlick AC, et al., A phase II study of the MEK1/MEK2 inhibitor GSK1120212 in metastatic BRAF-V600E or K mutant cutaneous melanoma patients previously treated with or without a BRAF inhibitor. J Clin Oncol 2013; 31: 482-489.
44. Infante JR, Falchook GS, Lawrence DP, et al., Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). J Clin Oncol 2011; 29: abstr. 8503.
45. Flaherty KT, Infante JR, Daud A, et al., Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-1703.
46. Oberholzer PA, Kee D, Dziunycz P, et al., RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012; 30: 316-321.
47. Kefford R, Miller W, Tan D, et al., Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors. J Clin Oncol 2013; 31: abstr. 8503.
48. Handolias D, Salemi R, Murray W, et al., Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell Melanoma Res 2010; 23: 210-215.
49. Curtin JA, Fridlyand J, Kageshita T, et al., Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-2147.
50. Carvajal RD, Antonescu CR, Wolchok JD, et al., KIT as a therapeutic target in metastatic melanoma. J Am Med Assoc 2011; 305: 2327-2334.
51. Guo J, Si L, Kong Y, et al., Phase II, open-label, single arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011; 29: 2904-2909.
52. Woodman SE, Trent JC, Stemke-Hale K, et al., Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 2009; 8: 2079-2085.
53. Kluger HM, Dudek AZ, McCann C, et al., A phase 2 trial of dasatinib in advanced melanoma. Cancer 2011; 117: 2202-2208.
54. Minor DR, Kashani-Sabet M, Garrido M, et al., Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res 2012; 18: 1457-1463.
55. Atkins MB,. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 2006; 12: 2353-2358.
56. Ribas A, Butterfield LH, Glaspy JA, et al., Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003: 21: 2415-2432.
57. Hodi FS, O'Day SJ, McDermott DF, et al., Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
58. Beck KE, Blansfield JA, Tran KQ, et al., Enterocolitis in patients with cancer after antibody blockade of cytotoxic T lymphocyte-associated antigen 4. J Clin Oncol 2006; 24: 2283-2289.
59. Robinson MR, Chan CC, Yang JC, et al., Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma a new cause of uveitis. J Immunother 2004; 27: 478-479.
60. Robert C, Thomas L, Bondarenko I, et al., Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
61. Dong H, Strome SE, Salomao DR, et al., Tumor-associated B7-H1 promotes T-cell apoptosis a potential mechanism of immune evasion. Nat Med 2002; 8: 793-800.
62. Iwai Y, Ishida M, Tanaka Y, et al., Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PDL1 blockade. Proc Natl Acad Sci USA 2002; 99: 12293-12297.
63. + T cells. Cancer Res 2004; 64: 1140-1145.
64. Okazaki T, Honjo T,. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007; 19: 813-824.
65. Topalian SL, Hodi FS, Brahmer JR, et al., Safety, activity and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
66. Brahmer JR, Tykodi SS, Chow LQ, et al., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465.
67. Hamid O, Robert C, Daud A, et al., Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-144.
68. Sznol M, Kluger H, Hodi F, et al., Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol 2013; 31: abstr. 9006.
69. Curran MA, Montalvo W, Yagita H, et al., PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Nat Acad Sci USA 2010; 107: 4275-4280.
70. Korman A, Chen B, Wang C, et al., Activity of anti-PD-1 in murine tumor models: role of 'host' PD-L1 and synergistic effect of anti-PD-1 and anti-CTLA-4. J Immunol 2007; 178: 48.37.
71. Wolchok JD, Kluger H, Callahan MK, et al., Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-133.
72. Weber J, Kudchadkar R, Gibney G, et al., Phase I/II trial of PD-1 antibody nivolumab with peptide vaccine in patients naive to or that failed ipilimumab. J Clin Oncol 2013; 31: abstr. no. 9011.
73. Ribas A, Hersey P, Middleton MR, et al., New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res 2012; 18: 336-341.
74. Begley J, Ribas A,. Targeted therapies to improve tumor immunotherapy. Clin Cancer Res 2008; 14: 4385-4391.
75. Wilmott JS, Long GV, Howle JR, et al., Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012; 18: 1386-1394.
76. Frederick DT, Piris A, Cogdill AP, et al., BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013; 19: 1225-1231.
77. Boni A, Cogdill AP, Dang P, et al., Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010; 70: 5213-5219.
78. Koya RC, Mok S, Otte N, et al., BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res 2012; 72: 3928-3937.
79. Knight DA, Ngiow SF, Li M, et al., Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest 2013; 123: 1371-1381.
80. Hooijkaas A, Gadiot J, Morrow M, et al., Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. Oncoimmunology 2012; 1: 609-617.
81. Ribas A., Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368: 1365-1366.
82. + T cell memory and tumor immunity. Immunity 2011; 34: 541-553.
83. + T cell fate by regulating the expression of transcription factors T-bet and eomesodermin. Immunity 2010; 32: 67-78.
84. Ribas A, Wolchok JD,. Combining cancer immunotherapy and targeted therapy. Curr Opin Immunol 2013; 25: 291-296.
85. Dahlman KB, Xia J, Hutchinson K, et al., BRAF (L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov 2012; 2: 791-797.
86. Garraway LA, Baselga J,. Whole-genome sequencing and cancer therapy: is too much ever enough? Cancer Discov 2012; 2: 766-768.